Levofolic

Levoleucovorin Disodium, the active ingredient in Levofolic, is a folate analog presented as an injectable solution for intravenous use. It is employed to reduce toxicity from certain chemotherapy agents and to support patients with folate deficiency, and is indicated in clinical protocols for rescue therapy following high‑dose methotrexate or 5‑fluorouracil treatment.

GNH USA supplies Levofolic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide through regulated distribution channels.

Levofolic (Levoleucovorin Disodium) is used in clinical settings to manage folate‑related toxicity and deficiency. - Methotrexate toxicity: provides rescue to lessen hematologic and mucosal adverse effects. - 5‑Fluorouracil toxicity: mitigates severe mucositis and diarrhea associated with treatment. - Folate deficiency: restores normal folate‑dependent metabolic processes in patients with inadequate folate status.

Levofolic may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional emesis following infusion. - Rash: transient skin erythema or pruritus. - Headache: mild to moderate headache during or after administration. - Fatigue: generalized tiredness reported by some patients. - Flushing: brief warmth or redness of the skin.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Acute renal dysfunction: sudden decrease in kidney function. - Electrolyte imbalance: notable changes in potassium or magnesium levels. - Thromboembolic events: rare clot formation in veins or arteries.

When using Levofolic, clinicians should observe several safety considerations. - Renal function: assess baseline and monitor during therapy. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Electrolytes: monitor serum levels, especially potassium and magnesium. - Concurrent antifolates: avoid co‑administration that may diminish efficacy. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Levofolic can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - High‑dose folic acid supplementation: may reduce therapeutic effect of antifolate chemotherapy. - Pemetrexed: concurrent use may increase toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may impair renal clearance of Levofolic. - Aminoglycoside antibiotics: potential additive nephrotoxicity. - Loop diuretics: may exacerbate electrolyte disturbances.